These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29929374)

  • 1. Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment.
    Giancola ML; Balestra P; Ammassari A; Ricottini M; Lorenzini P; Angeletti C; Bellagamba R; Tommasi C; Tempestilli M; Zaccarelli M; Pinnetti C; Gallo AL; Antinori A; Narciso P; Nicastri E
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):907-908. PubMed ID: 29929374
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
    Havenith T; Burger D; Visschers MJ; Schippers J; Oude Lashof A
    Ther Drug Monit; 2017 Apr; 39(2):91-92. PubMed ID: 28230617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
    Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-tablet antiretroviral treatment (once daily).
    Andany N; Gold WL
    CMAJ; 2016 Sep; 188(13):971. PubMed ID: 27221274
    [No Abstract]   [Full Text] [Related]  

  • 6. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 10. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
    J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emtricitabine/tenofovir disoproxil fumarate.
    Dando TM; Wagstaff AJ
    Drugs; 2004; 64(18):2075-82; discussion 2083-4. PubMed ID: 15341498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
    Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.